Knight Therapeutics (GUD), the Healthcare company was revisited today, and remains undervalued for at least one analyst on the street. Analyst David Novak from Raymond James rated Knight Therapeutics (GUD) a Buy, setting a C$10.25 price target.
According to TipRanks.com, Novak is ranked #2382 out of 5282 analysts.
Knight Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of C$9.42.
The company has a one-year high of C$8.81 and a one-year low of C$7.27. Currently, Knight Therapeutics has an average volume of 352.4K.
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite.
The company’s shares closed on Friday at C$7.41, close to its 52-week low of C$7.27.
